{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Soria A"],"pubmed_abstract":["<h4>Purpose</h4>Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B) has demonstrated efficacy and tolerability in phase III clinical trials, and is the standard of care for advanced/metastatic BRAF<sup>V600</sup>-mutant melanoma. However, real-life evidence is limited, particularly in patients pre-treated with immune checkpoint inhibitors (ICI).<h4>Patients and methods</h4>BECARE GEM 2002 was a retrospective, non-interventional study aimed at investigating the real-world effectiveness and tolerability of EB in patients with unresectable or metastatic BRAF<sup>V600</sup>-mutant melanoma conducted at 21 sites in Spain. The primary objective of this study was to characterise the population of patients receiving EB and assess the efficacy and tolerability of EB in real life."],"journal":["Frontiers in oncology"],"pagination":["1466185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11897558"],"repository":["biostudies-literature"],"pubmed_title":["Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF&lt;sup&gt;V600&lt;/sup&gt;-mutant melanoma in Spain: the BECARE (GEM-2002) trial."],"pmcid":["PMC11897558"],"pubmed_authors":["Cerezuela-Fuentes P","Lopez Castro R","Sanchez Maurino P","Garcia Galindo R","Soria A","Fra Rodriguez J","Garcia Sanchez L","Sequero S","Cunquero-Tomas AJ","Campos B","Puertolas T","Lopez P","Aguayo C","Gutierrez Sanz L","Crespo G","Diaz-Beveridge R","Benitez G","Ayala de Miguel P","Valdivia J","Espinosa E","Munoz-Couselo E","Serrano Domingo JJ"],"additional_accession":[]},"is_claimable":false,"name":"Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF&lt;sup&gt;V600&lt;/sup&gt;-mutant melanoma in Spain: the BECARE (GEM-2002) trial.","description":"<h4>Purpose</h4>Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B) has demonstrated efficacy and tolerability in phase III clinical trials, and is the standard of care for advanced/metastatic BRAF<sup>V600</sup>-mutant melanoma. However, real-life evidence is limited, particularly in patients pre-treated with immune checkpoint inhibitors (ICI).<h4>Patients and methods</h4>BECARE GEM 2002 was a retrospective, non-interventional study aimed at investigating the real-world effectiveness and tolerability of EB in patients with unresectable or metastatic BRAF<sup>V600</sup>-mutant melanoma conducted at 21 sites in Spain. The primary objective of this study was to characterise the population of patients receiving EB and assess the efficacy and tolerability of EB in real life.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-04-04T01:28:35.671Z","creation":"2025-04-04T01:28:35.671Z"},"accession":"S-EPMC11897558","cross_references":{"pubmed":["40078188"],"doi":["10.3389/fonc.2025.1466185"]}}